Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome (RAZANT)

Ferring

Status: Terminated

Conditions: Growth Disorders

Treatments: Drug: Zomacton

Study type: Observational

Funder types: Industry

Identifiers

NCT03274973

000302

Details and patient eligibility

About

Assessment of long-term effectiveness of ZOMACTON in treatment of Growth Hormone Deficiency or growth retardation due to Ullrich-Turner Syndrome and assessment of compliance and adherence, optionally with the aid of an electronic app or patient diary.

Enrollment: 4 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pediatric patients (< 18 years) with growth hormone deficiency or growth retardation due to Ullrich-Turner-Syndrome
• Patients already receiving or who have been prescribed Zomacton® de novo according to its German label; the decision to prescribe Zomacton® was made independently from participation and prior to enrollment in this study.
• Patient and their parents (or legal representatives) who are willing and able to provide signed informed consent for use of their personal data.

Exclusion criteria

• Participation in an interventional clinical study within the last 30 days prior to baseline visit or during the follow-up period

Trial design

4 participants in 1 patient group

Zomacton

Treatment:

Drug: Zomacton